---
title: "YIBAI PHARMACEUTICAL: Children's cough syrup resumes production and sales"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/257689596.md"
description: "YIBAI PHARMACEUTICAL announced the resumption of production and sales of its children's cough syrup. The product was suspended from production in August 2025 due to a notice from the Guizhou Provincial Drug Administration, and the suspension was lifted on September 16, 2025, after rectification. From 2021 to 2024, the operating revenues of this product were 3.42 million yuan, 4.32 million yuan, 8.38 million yuan, and 1.51 million yuan, accounting for a small proportion of the company's total revenue. The impact of resuming production and sales on the company's performance is expected to be minimal"
datetime: "2025-09-17T09:14:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257689596.md)
  - [en](https://longbridge.com/en/news/257689596.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257689596.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/257689596.md) | [繁體中文](https://longbridge.com/zh-HK/news/257689596.md)


# YIBAI PHARMACEUTICAL: Children's cough syrup resumes production and sales

YIBAI PHARMACEUTICAL announced that the company suspended the production and sale of children's cough syrup in August 2025 due to receiving the "Notice of Suspension of Production and Sales" from the Guizhou Provincial Drug Administration. After rectification, the company received the "Notice of Lifting Suspension of Production/Sales" on September 16, 2025, and the suspension measures for the children's cough syrup product have been lifted. Currently, the company has resumed the production and sale of this product. From 2021 to 2024, the operating revenues of children's cough syrup were 3.42 million yuan, 4.32 million yuan, 8.38 million yuan, and 1.51 million yuan, respectively, accounting for a small proportion of the company's consolidated revenue during the same period. It is expected that the resumption of production and sales will not have a significant impact on the company's performance

### 相关股票

- [YIBAI PHARMACEUTICAL (600594.CN)](https://longbridge.com/zh-CN/quote/600594.CN.md)

## 相关资讯与研究

- [The Highest-Rated Healthcare Stock to Buy Now to Hedge Against Oil Price Shocks](https://longbridge.com/zh-CN/news/279670454.md)
- [The best healthcare stocks to buy with $50 right now](https://longbridge.com/zh-CN/news/279614347.md)
- [Bondi to 'follow the law' after House subpoena in Epstein probe](https://longbridge.com/zh-CN/news/279723055.md)
- [Kerala govt approves universal health coverage for wider healthcare access](https://longbridge.com/zh-CN/news/279141050.md)
- [China Medical System Lifts Revenue and Dividend as Innovation and Overseas Push Gather Pace](https://longbridge.com/zh-CN/news/279289179.md)